ProtAffin
ProtAffin is focussed on protein-glycosaminoglycan interactions as a target for drug discovery. The company is developing engineered chemokines as protein-based glycosaminoglycan (GAG) antagonists. The pipeline products have anti-inflammatory activity by specifically inhibiting leukocyte trafficking to inflammatory sites.
ProtAffin is focussed on protein-glycosaminoglycan interactions as a target for drug discovery. The company is developing engineered chemokines as protein-based glycosaminoglycan (GAG) antagonists. The pipeline products have anti-inflammatory activity by specifically inhibiting leukocyte trafficking to inflammatory sites.
ProtAffin is an early stage biotechnology company in Austria, spun-out from the Karl-Franzens University of Graz. ProtAffin Biotechnology AG was founded in July 2005 by Andreas Kungl and Jason Slingsby and is located in Graz, Styria, in Southeast Austria.
Contact ProtAffin
ProtAffin Biotechnologie AG<BR>Impulszentrum Graz-West<BR>Reininghausstraße 13<BR>A-8020 Graz<BR>Austria
Website link